Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal (NASDAQ:AMRX)
Summary
Amneal (AMRX) Q1 2026 earnings call recap: Kashiv BioSciences acquisition, biosimilars strategy, raised 2026 guidance, synergies & outlook—read now.
Description
Amneal (AMRX) Q1 2026 earnings call recap: Kashiv BioSciences acquisition, biosimilars strategy, raised 2026 guidance, synergies & outlook—read now.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source